Business
Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio Breast Cancer Symposium
New data will be presented about Precise® Molecular Residual Disease (MRD) Test and MyRisk® Hereditary Cancer Test SALT LAKE CITY, Dec. 09, 2025 (GLOBE
About this update from Myriad Genetics, Inc.
[{"type":"text","content":"New data will be presented about Precise® Molecular Residual Disease (MRD) Test and MyRisk® Hereditary Cancer Test\nSALT LAKE CITY, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will present new data in eight abstracts at the 2025 San Antonio Breast Cancer Symposium® (SABCS). The company will share the latest advances in the MyRisk® Hereditary Cancer Test that support guideline-driven treatment decisions. Additionally, the company is presenting data on its Precise® Molecular Residual Disease (MRD) Test, an ultrasensitive, second-generation pan-tumor MRD test that is especially impactful for low-tumor-shedding cancers, such as breast cancer. It has high sensitivity and specificity at low tumor fraction.1 “I am thrilled that we are sharing some very strong data at SABCS from multiple breast-cancer studies that used Precise MRD,” said Dale Muzzey, PhD, Chief Scientific Officer, Myriad Genetics. “Each study showcases the benefit of ultrasensitive and quantitative ctDNA testing, as we observed noteworthy correspondence with clinical outcomes of interest. I’m also pleased that, in addition to MRD studies, we are sharing data about germline testing, somatic testing, and polygenic risk assessment, all areas of excellence for Myriad that underscore our commitment to serving the cancer care continuum.” Myriad will sponsor a session at the Product Theater, where Gregory Vidal, MD, PhD, associate professor at the University of Tennessee Health Science Center, and Sara Mokhtary-Myers, MS, CGC, certified genetic counselor and Genetics Program Coordinator at Texas Oncology, will discuss the evolving role of tumor genomic and germline testing in breast cancer care. The session will be held on Wednesday, Dec. 10, 2:30–3:30 p.m. Myriad Genetics PresentationsPersonalized Whole-Genome-Based ctDNA Dynamics During Neoadjuvant Therapy Across Breast Cancer Subtypes: Early Insights From MONITOR-BreastAbstract #3552, Presentation # PS1-13-11Wednesday, Dec. 10, 12:30-2:00 pm (CST), Exhibit HallPresenter: Julia Foldi, MD, PhD, University of Pittsburgh Medical Center Ultra-sensitive Molecular Residual Disease Detection in Breast Cancer Using Whole-Genome Sequencing-Based Personalized ctDNA Panels: Preliminary Results from the MONSTAR-SCREEN-3 Project Pre...